Search results
Jun 26, 2024 · Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers.
Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing.
Delivering Value to Investors. A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments.
Jan 10, 2022 · The company expects another strong year in 2022, with consolidated revenue guidance of $5.15 billion to $5.24 billion, or growth of 14% to 16% year-over-year, as sequencing awareness, demand, and adoption increase.
May 26, 2022 · SINGAPORE, 26 May 2022 – Precision Health Research, Singapore (PRECISE), the central entity implementing Singapore’s National Precision Medicine (NPM) strategy, and Illumina, Inc (Illumina), a leader in genomics technology, announced today a strategic partnership to sequence and analyse 100,000 Singaporean whole genomes (SG100K ...
